

Carfilzomib (KYPROLIS)

Criteria for Use

July 2025

VA Pharmacy Benefits Management Services and National Formulary Committee

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

See the VA National Formulary Committee Monograph on this drug at the [PBM INTRAnet](#) site for further information.

Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive carfilzomib

- Absolute Neutrophil Count < 1000/ μ L and/or platelet count < 50,000/ μ L (<30,000/ mm^3 if myeloma involvement in bone marrow > 50%)
- Total bilirubin > 1.5x upper limit of normal (unless Gilbert's syndrome or liver involvement) and/or alanine transaminase (ALT), aspartate transaminase (AST) and alkaline phosphatase > 3x upper limit of normal (unless liver involvement)
- Clinically significant cardiovascular disease[^]
- Grade 3 or 4 peripheral neuropathy
- Active or uncontrolled infection
- Unmanageable drug-drug interaction
- Known pregnancy
- Lactating

[^]Baseline Left Ventricular Ejection Fraction < 50% via MUGA or echocardiography; uncontrolled hypertension or arrhythmia; myocardial infarction within prior 6 months; symptomatic congestive heart failure (New York Heart Assoc Class 3-4)

Inclusion Criteria

ALL the following criteria must be met.

- Previously treated multiple myeloma.
- Care is provided by a VA/VA Community Care oncology or hematology provider.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Goals of care and role of Palliative Care consult have been discussed and documented.
- Venous thromboembolism (VTE) risk scoring (i.e. SAVED, IMPEDE) performed for consideration of VTE prophylaxis

Additional Inclusion Criteria *if applicable*

- For patients who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy and for 6 months after stopping treatment.
- For patients with partners who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy and for 3 months after stopping treatment.

Other Justification